Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1

Patrick J. Hensley, Roland Seiler, Harry Herr, Kent W. Mouw, Gopa Iyer, Lars Dyrskjøt, Roman Nawroth, Peter Goebell, Bernd Schmitz-Drager, Tilman Todenhofer, Peter C. Black, Ashish M. Kamat, Stephen B. Williams

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.

Original languageEnglish (US)
Pages (from-to)307-312
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Issue number7
StatePublished - Jul 2023


  • Bladder cancer
  • DNA damage response
  • Genetic alteration
  • Neoadjuvant therapy
  • Predictors

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1'. Together they form a unique fingerprint.

Cite this